New combinations and immunotherapies for melanoma: latest evidence and clinical utility. (Q38133560)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2013

edit

Language	Label	Description	Also known as
English	New combinations and immunotherapies for melanoma: latest evidence and clinical utility.	scientific article published on September 2013

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

title

New combinations and immunotherapies for melanoma: latest evidence and clinical utility (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

main subject

immunotherapy

1 reference

based on heuristic

inferred from title

author

Alexander M Menzies

series ordinal

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

Georgina V. Long

series ordinal

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

Georgina V. Long

series ordinal

2

object named as

Georgina V Long

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

retrieved

29 August 2017

Alexander M Menzies

series ordinal

1

object named as

Alexander M Menzies

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

retrieved

29 August 2017

publication date

1 September 2013

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

published in

Therapeutic advances in medical oncology

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

volume

5

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

issue

5

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

page(s)

278-285

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

cites work

Hepatotoxicity with combination of vemurafenib and ipilimumab

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Final version of 2009 AJCC melanoma staging and classification

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

6 September 2017

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

14 September 2017

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

23 June 2018

Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

31 August 2018

BRAF inhibitor activity in V600R metastatic melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

31 August 2018

Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

31 August 2018

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752177

retrieved

31 August 2018

Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1758834013499637

retrieved

21 January 2018

Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1758834013499637

retrieved

21 January 2018

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1758834013499637

retrieved

21 January 2018

Identifiers

DOI

10.1177/1758834013499637

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

PMC publication ID

3752177

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

PubMed publication ID

23997828

1 reference

stated in

Europe PubMed Central

PMC publication ID

3752177

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23997828%20AND%20SRC:MED&resulttype=core&format=json

retrieved

8 March 2020

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38133560&oldid=1936893920"